VolitionRx (OTC:VNRX) Has $6 Target At Maxim Group.

May 17, 2018 - By Richard Doty

VolitionRx Limited (NYSEAMERICAN:VNRX) Corporate Logo

Big Money Sentiment decreased to 1.2 in 2017 Q4. It has change of 5.80, from 2017Q3’s 7. The ratio fall due to VolitionRx Limited positioning: 3 sold and 2 reduced. 2 funds amassed stakes and 4 increased stakes. Investors holded 9.30 million in 2017Q3 but now own 4.52 million shares or 51.36% less.

Garrison Bradford Associates invested 0.04% of its capital in VolitionRx Limited (NYSEAMERICAN:VNRX). Royal Bancorporation Of Canada accumulated 14,007 shs. Brown Brothers Harriman And Communications accumulated 0% or 3,823 shs. Knoll Cap Mgmt Ltd Partnership reported 0.91% in VolitionRx Limited (NYSEAMERICAN:VNRX). Blackrock owns 11,219 shs. Bridgeway Cap Mgmt holds 109,400 shs. Bancorp Of Mellon holds 0% or 10,335 shs. Bessemer owns 10,000 shs or 0% of their US capital. Northern Corp reported 22,714 shs stake. Leisure Mngmt holds 74,863 shs or 0.18% of its capital. The New York-based Lagoda Inv Management Limited Partnership has invested 3.94% in VolitionRx Limited (NYSEAMERICAN:VNRX). Creative Planning owns 13,200 shs for 0% of their capital. Vanguard Group Inc Inc reported 0% of its capital in VolitionRx Limited (NYSEAMERICAN:VNRX). Geode Mngmt Limited Liability Company has 0% invested in VolitionRx Limited (NYSEAMERICAN:VNRX) for 100,890 shs. Morgan Stanley has invested 0% in VolitionRx Limited (NYSEAMERICAN:VNRX).

What Price Target Has Maxim Group Given VolitionRx (OTC:VNRX)

With Buy rating that indicates 166.67 % upside potential on VolitionRx (OTC:VNRX), Maxim Group has started coverage of VNRX’s shares on Wednesday morning.

VNRX hit $2.25 during the last trading session after $0.18 change.VolitionRx Limited has 145,762 shares volume, 3.92% up from normal. VNRX is downtrending and has moved 42.82% since May 17, 2017. The stock underperformed the S&P500 by 54.37%.

VolitionRx Limited (NYSEAMERICAN:VNRX)’s quarterly earnings will be announced on August, 8., according to Zacks. The EPS diference is $0.04 or 30.77 % down from last years number. Previous year: $-0.13; Analysts forcast: $-0.17. 0.00 % EPS growth is what Wall Street’s forecasts after $-0.17 reported EPS previous quarter.

VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide.The firm is worth $67.57 million. The firm develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform.Currently it has negative earnings.

VolitionRx Limited (NYSEAMERICAN:VNRX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: